Overview
DarioHealth Q3 2025 revenue declined year-over-year, missing analyst expectations
Net income for Q3 2025 beat analyst estimates despite revenue decline
Operating income for Q3 2025 missed analyst expectations
Outlook
Dario targets $12.4 mln in new business for 2025
Company expects to reach cashflow breakeven by late 2026 to early 2027
Dario's 2026 commercial pipeline stands at $69 mln
Result Drivers
REVENUE DECLINE - Revenue decreased due to transition from one-time revenues to high-margin recurring revenue model
MULTI-CONDITION PLATFORM - Over 50% of new clients chose multi-condition offering, driving adoption
OPERATING EXPENSES REDUCTION - Operating expenses decreased by 31% in first nine months of 2025 due to operational efficiencies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $5 mln | $5.67 mln (4 Analysts) |
Q3 Net Income | Beat | -$10.50 mln | -$12.44 mln (4 Analysts) |
Q3 Operating Income | Miss | -$9.50 mln | -$8.57 mln (3 Analysts) |
Q3 Gross Profit | $3 mln | ||
Q3 Operating Expenses | $12.50 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for DarioHealth Corp is $25.00, about 53% above its November 12 closing price of $11.75
Press Release: ID:nPn9jsvJya
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)